A Partner in Health
A new chapter, a new approach. Collaborating with physicians and other healthcare professionals, focusing on R&D and maintaining clinical leadership add up to innovative medical solutions that make a difference.
Work with Us
Join Covidien, where we appreciate your talent, your experience and your passion for your work. Our culture thrives because we invest in our colleagues' growth and reward their efforts.
COV (NYSE)
| Price: | $53.48 |
| Change: | (0.06) |
| Volume: | 85,900 |
Minimum 20 minute delay
-
8/19/2008 8:03:00 AM
Covidien Announces Establishment of Covidien Ventures
HAMILTON, Bermuda--(BUSINESS WIRE)--Aug. 19, 2008--Covidien Ltd. (NYSE: COV; BSX: COV), a leading global provider of healthcare products, today announced that it has established Covidien Ventures, a corporate venture capital function. Covidien Ventures will invest in areas of strategic im...
-
8/18/2008 9:01:00 AM
Mallinckrodt Baker and Rubicon Research Sign Agreement for Performance Excipient Development
Companies collaborate to provide leading-edge drug delivery technology PHILLIPSBURG, N.J., Aug 18, 2008 (BUSINESS WIRE) -- Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Mallinckrodt Baker business has entered into ... -
8/7/2008 9:01:00 AM
Covidien Acquires CardioDigital Inc. Technology
Innovative Technology Offers Clinical Advancements in Patient Monitoring
MANSFIELD, Mass.--(BUSINESS WIRE)--Aug. 7, 2008--Covidien (NYSE: COV, BSX: COV), a leading global supplier of healthcare products, today announced the acquisition of technolog...
-
8/5/2008 6:01:00 AM
Covidien Reports Third-Quarter 2008 Results
- Third-quarter net sales up 14%, led by double-digit increases in Medical Devices, Imaging Solutions and Pharmaceutical Products
- Third-quarter diluted GAAP earnings per share from continuing operations were $0.65; excluding specified items, adju...